Journal
GENES & DEVELOPMENT
Volume 18, Issue 5, Pages 528-540Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.1167804
Keywords
PPAR gamma; nuclear receptor; breast cancer; mammary tumors; Wnt signaling
Categories
Funding
- NCI NIH HHS [P01 CA054418, CA54418] Funding Source: Medline
Ask authors/readers for more resources
Breast cancer cell lines that express the nuclear peroxisome proliferator-activated receptor gamma (PPARgamma) can be prompted to undergo growth arrest and differentiation when treated with synthetic PPARgamma ligands. To evaluate the therapeutic potential of increased PPARgamma signaling in vivo, we generated transgenic mice that express a constitutively active form of PPARgamma in mammary gland. These mice are indistinguishable from their wild-type littermates. However, when bred to a transgenic strain prone to mammary gland cancer, bigenic animals develop tumors with greatly accelerated kinetics. Surprisingly, in spite of their more malignant nature, bigenic tumors are more secretory and differentiated. The molecular basis of this tumor-promoting effect may be an increase in Wnt signaling, as ligand activation of PPARgamma potentiates Wnt function in an in vivo model of this pathway. These results suggest that once an initiating event has taken place, increased PPARgamma signaling serves as a tumor promoter in the mammary gland.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available